The Silverstein Foundation In the News
The Silverstein Foundation has been featured in national and international publications and broadcast media. Explore the thinks below to see and hear what others are saying about the Foundation and our Founder’s story.
Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001
Prevail Therapeutics Inc. today announced that the United States Patent and Trademark Office (USPTO) on November 17, 2020 issued a composition of matter patent, with claims directed to the AAV vector used in PR001, Prevail’s experimental gene therapy program for the treatment of Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD).
Aspen Neuroscience Announces $70 Million Series A Financing
Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, today announced the close of its Series A funding round of $70 million. OrbiMed led the investment round with participation from ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, Section 32, and Sam Altman.
The Silverstein Foundation and Q-State Biosciences Launch Chamishi Therapeutics
The Silverstein Foundation for Parkinson’s with GBA and Q-State Biosciences today announced the formation and launch of Chamishi Therapeutics, a drug discovery and development company focused on neurodegenerative diseases and other related disorders. Chamishi will initially focus on developing antisense oligonucleotide (ASO) therapies for Glucosylceramidase Beta Acid (GBA)-Parkinson’s disease.
The Michael J. Fox Foundation and The Silverstein Foundation for Parkinson’s with GBA Grant Nearly $3 Million to Studies into Disease’s Most Common Known Genetic Contributor
Mutations in the GBA gene are the most common genetic risk factors for Parkinson’s, affecting about 10 percent of the more than 6 million people estimated to have the disease. The projects selected through this joint funding program aim to better understand the effect of GBA mutations – and the role of GBA more generally – and advance treatments against this target.